SEC Form 4 · accession 0001596771-19-000017

Nuwellis, Inc. · NUWE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — CEO and President · Director

Period of report

Mar 12, 2019

Accepted (ET)

Mar 12, 2019 · 4:40 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001506492

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Mar 12, 2019	P	9,523	$5.25	A	11,615	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series 1 Warrant to Purchase Common Stock (right to buy)^F1	$5.25	Mar 12, 2019	P	9,523	A	Mar 12, 2019	Mar 12, 2024	Common Stock	9,523	9,523	D
Series 2 Warrant to Purchase Common Stock (right to buy)^F1,F3	$5.25	Mar 12, 2019	P	9,523	A	Mar 12, 2019	—	Common Stock	9,523	9,523	D

F1The reporting person purchased Class A Units, which consisted of one share of common stock, a Series 1 warrant to purchase one share of common stock, and a Series 2 warrant to purchase one share of common stock, in an underwritten public offering by the issuer at a price of $5.25 per unit. The offering closed on March 12, 2019.
F2On January 2, 2019, the issuer effected a 1-for-14 reverse stock split of the issued and outstanding shares of its common stock. Upon effectiveness of the reverse stock split, every 14 shares of common stock was automatically converted into one share of common stock.
F3The Series 2 warrant expires on the earlier of the eighteen-month anniversary of the date of issuance and the 30th trading day following public announcement by the issuer of receipt from the U.S. Food and Drug Administration of clearance or approval of a modification to the product label for the Aquadex FlexFlow system to include pediatric patients.